ipilimumab,nivolumab
bms
['sclc', 'congrat', 'energy', 'nsclc']
congratulation to at #asco2022 for the presentation of the results of energy trial. another study concerning elderly nsclc patients from 
Medical oncologist. Institut de Cancérologie Strasbourg Europe